Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

Inovio Pharmaceuticals Inc. closed 86.10% short of its 52-week high of $14.75, which the company achieved on April 1st.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

PLYMOUTH MEETING, PA — INOVIO Pharmaceuticals Inc. (NASDAQ: INO) has announced the recent award of equity grants to two new employees as part of its 2022 Inducement Plan. The company’s ...

Shares of Inovio Pharmaceuticals stock opened at $1.98 on Wednesday. The company has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89. Inovio Pharmaceuticals has a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.

And our discussion with Inovio. It's a pleasure to introduce Jacqui Shea, CEO and President. Thank you so much for joining us here today, Jackie. I'll turn it over to you. Thank you so much ...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.